EPCAM and breast cancer: Oppositely, loss of epithelial traits during partial EMT, as measured by EpCAM reduction and gain in vimentin32, might be associated with decreased proliferation and increased migration, or primarily with increased treatment resistance as demonstrated for prostate, pancreatic, breast cancer and HNSCC15,16,26,32.